Suppr超能文献

噻吩并[3,2-b]吡咯-5-甲酰胺作为组蛋白赖氨酸去甲基化酶KDM1A/LSD1的新型可逆抑制剂。第1部分:高通量筛选与初步探索。

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration.

作者信息

Sartori Luca, Mercurio Ciro, Amigoni Federica, Cappa Anna, Fagá Giovanni, Fattori Raimondo, Legnaghi Elena, Ciossani Giuseppe, Mattevi Andrea, Meroni Giuseppe, Moretti Loris, Cecatiello Valentina, Pasqualato Sebastiano, Romussi Alessia, Thaler Florian, Trifiró Paolo, Villa Manuela, Vultaggio Stefania, Botrugno Oronza A, Dessanti Paola, Minucci Saverio, Zagarrí Elisa, Carettoni Daniele, Iuzzolino Lucia, Varasi Mario, Vianello Paola

机构信息

Department of Experimental Oncology, Academic Drug Discovery, European Institute of Oncology , Via Adamello 16, 20139 Milano, Italy.

Genextra Group, DAC s.r.l. , Via Adamello 16, 20139 Milano, Italy.

出版信息

J Med Chem. 2017 Mar 9;60(5):1673-1692. doi: 10.1021/acs.jmedchem.6b01018. Epub 2017 Feb 27.

Abstract

Lysine specific demethylase 1 KDM1A (LSD1) regulates histone methylation and it is increasingly recognized as a potential therapeutic target in oncology. We report on a high-throughput screening campaign performed on KDM1A/CoREST, using a time-resolved fluorescence resonance energy transfer (TR-FRET) technology, to identify reversible inhibitors. The screening led to 115 hits for which we determined biochemical IC, thus identifying four chemical series. After data analysis, we have prioritized the chemical series of N-phenyl-4H-thieno[3, 2-b]pyrrole-5-carboxamide for which we obtained X-ray structures of the most potent hit (compound 19, IC = 2.9 μM) in complex with the enzyme. Initial expansion of this chemical class, both modifying core structure and decorating benzamide moiety, was directed toward the definition of the moieties responsible for the interaction with the enzyme. Preliminary optimization led to compound 90, which inhibited the enzyme with a submicromolar IC (0.162 μM), capable of inhibiting the target in cells.

摘要

赖氨酸特异性去甲基化酶1(KDM1A,又称LSD1)可调节组蛋白甲基化,并且越来越被认为是肿瘤学中的一个潜在治疗靶点。我们报告了一项使用时间分辨荧光共振能量转移(TR-FRET)技术对KDM1A/CoREST进行的高通量筛选活动,以鉴定可逆抑制剂。该筛选产生了115个命中化合物,我们测定了它们的生化半数抑制浓度(IC),从而确定了四个化学系列。数据分析后,我们对N-苯基-4H-噻吩并[3,2-b]吡咯-5-甲酰胺化学系列进行了优先级排序,我们获得了该系列中最有效命中化合物(化合物19,IC = 2.9 μM)与该酶复合物的X射线晶体结构。对这一化学类别进行初步扩展,包括修饰核心结构和修饰苯甲酰胺部分,旨在确定与该酶相互作用的部分。初步优化得到了化合物90,它以亚微摩尔级的IC(0.162 μM)抑制该酶,并且能够在细胞中抑制该靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验